2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
02:45 p.m. - 04:15 p.m.
MCCNO - Great Hall BC
Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Transplantation, Diseases, Myeloid Malignancies, Acute Myeloid Malignancies, Measurable Residual Disease, Research, AML, Clinical Research, Clinical Trials, Study Population, Human, Adult
PAPER

902 Ziftomenib combined with intensive induction (7+3) and quizartinib for newly diagnosed NPM1-m and FLT3-ITD+ acute myeloid leukemia (AML): Preliminary results from KOMET-007

Jesus D Gonzalez-Lugo, MD, Amer M. Zeidan, MD2, Tara L. Lin, MD3, Suresh Kumar Balasubramanian, MD4, Amir T. Fathi, MD5, Eunice Sue Wang, MD6, Keith W. Pratz, MD7, Ghayas C. Issa, MD8, Guru Subramanian Guru Murthy, MD9, Jessica Kaplan Altman, MD10, James Stewart Blachly, MD11, Stephen A. Strickland, MD12, Yazan F. Madanat, MD13, Joseph Jurcic, MD14, Christine M. McMahon, MD15, Kiran Naqvi16, Mohamad Khawandanah, MD17, Patrick W. Burke, MD18, Talha Badar, MD19, Gary J. Schiller, MD20, Anjali Sunder Advani, MD21, Gail J Roboz, MD22, Marcello Rotta23, Grerk Sutamtewagul, MD24, Clark Clark Alsfeld, MD25, Ayman Qasrawi, MD26, Hongling Zhang, MS27, Tianle Chen, PhD28, Harris Soifer, PhD29, Robert Sutphin, MD30, Valerie Chamberlain Santos31, Marcie Riches, MD, MS32, Daniel Corum, PhD33, Mollie Leoni, MD34, Harry P. Erba, MD35
1 Hematologic Malignancies and Cellular Therapeutics, Kansas City, Kansas, United States
2 2Yale University and Yale Comprehensive Cancer Center, New Haven, Connecticut, United States
3 3University of Kansas, Fairway, Kansas, United States
4 Karmanos Cancer Institute, Wayne State University, Detroit, Michigan, United States
5 Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, United States
6 Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States
7 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
9 Froedtert & Medical College of Wisconsin, Milwaukee, Wisconsin, United States
10 Northwestern University, Boston, United States
11 The Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
12 SCRI at TriStar Centennial, Nashville, Tennessee, United States
13 The University of Texas Southwestern Medical Center, Dallas, Texas, United States
14 Columbia University Irving Medical Center, New York, New York, United States
15 Anschutz Medical Campus, Division of Hematology, University of Colorado School of Medicine, Aurora, Colorado, United States
16 Chao Family Comprehensive Cancer Center, University of California Irvine Health, Orange, California, United States
17 University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City, Oklahoma, United States
18 University of Michigan, Ann Arbor, Michigan, United States
19 Mayo Clinic, Jacksonville, Florida, United States
20 David Geffen School of Medicine at UCLA, Los Angeles, California, United States
21 Taussig Cancer Institute, Cleveland Clinic, Cleveland, Ohio, United States
22 Weill Cornell Medicine and The New York Presbyterian Hospital, New York, New York, United States
23 Colorado Blood Cancer Institute, Denver, Colorado, United States
24 Holden Comprehensive Cancer Center, University of Iowa Healthcare, Iowa City, Iowa, United States
25 Ochsner MD Anderson Cancer Center, New Orleans, Louisiana, United States
26 University of Kentucky, Department of Internal Medicine, Lexington, Kentucky, United States
27 Kura Oncology, Inc., San Diego, California, United States
28 Kura Oncology, Inc., San Diego, California, United States
29 Kura Oncology, Inc., San Diego, California, United States
30 Kura Oncology, Inc., San Diego, California, United States
31 Kura Oncology, Inc., San Diego, California, United States
32 Kura Oncology, Inc., San Diego, California, United States
33 Kura Oncology, Inc., San Diego, California, United States
34 Kura Oncology, Inc., San Diego, United States
35 Duke Cancer Institute, Durham, North Carolina, United States


Introduction:
NPM1 mutations drive leukemogenesis in ~30% of AML, and FLT3 mutations are present in ~50% of NPM1-m AML. Ziftomenib is a potent, selective, oral menin inhibitor approved as monotherapy for adults with relapsed/refractory NPM1-m AML and has also shown encouraging clinical activity in combination regimens for newly diagnosed (ND) NPM1-m and KMT2A-r AML. As FLT3 is downstream of the menin-MLL pathway, combining ziftomenib with a FLT3 inhibitor may enhance antitumor activity. KOMET-007 (NCT05735184) is an ongoing, open-label, phase 1a/b dose-escalation/expansion study evaluating ziftomenib in combination with standard chemotherapies in NPM1-m or KMT2A-r AML. Here we report preliminary phase 1a results from KOMET-007 in patients with ND NPM1-m/FLT3 internal tandem duplication (ITD)+ AML treated with ziftomenib, daunorubicin/cytarabine (7+3) and the FLT3 inhibitor quizartinib.       

Methods: Adults (≥18y) with ND NPM1-m and FLT3-ITD+ (allelic ratio ≥0.05) AML eligible for intensive chemotherapy and FLT3-targeted therapy were enrolled and received ziftomenib 200, 400 or 600 mg once daily with standard 7+3 induction and quizartinib. Ziftomenib was administered continuously from Cycle 1 Day 8 of 7+3 onward; quizartinib was administered on Cycle 1 Days 8–21 per label. Consolidation consisted of high/intermediate-dose cytarabine with quizartinib on Days 6-19 and continuous ziftomenib. Primary endpoints were dose-limiting toxicities (DLTs), adverse events (AEs) and complete remission (CR; ELN 2022) rate. Secondary endpoints included composite CR (CRc; CR with full/partial/incomplete hematologic recovery) rate and duration of remission. Measurable residual disease (MRD) was assessed locally per institutional standards and centrally for NPM1/FLT3 by next-generation sequencing.

Results: As of June 16, 2026, 18 patients were enrolled and treated in phase 1a (9 at 200 mg, 9 at 400 mg); the 600 mg cohort (n=9) had fully enrolled, with all patients still in induction at time of data cutoff. Median age was 51y (range 39-64) for 200 mg and 55y (range 36-69) for 400 mg; 67% and 56% were male, and 100% had ECOG PS 0–1. Median follow-ups were 29.7 and 11.7 wks at 200 mg and 400 mg, respectively. No DLTs were observed. Grade (Gr)≥3 treatment-emergent AEs (TEAEs) occurred in 16 patients (89%; 9 at 200 mg, 7 at 400 mg), most commonly febrile neutropenia (44%; 6 at 200 mg, 2 at 400 mg), thrombocytopenia (39%; 4 at 200 mg, 3 at 400 mg), and anemia (22%; 4 at 400 mg). Gr≥3 ziftomenib-related TEAEs occurred in 4 patients (22%; 1 at 200 mg, 3 at 400 mg), most commonly febrile neutropenia (11%; 2 at 400 mg). No ziftomenib-related TEAEs led to ziftomenib discontinuation. There were no reported cases of differentiation syndrome. One Gr≥3 investigator-assessed QTc prolongation event (200 mg; unrelated to ziftomenib) occurred in the setting of concomitant QT-prolonging medications and electrolyte imbalances, resolved, and the patient resumed ziftomenib and quizartinib.

Among response-evaluable patients (≥1 post-baseline assessment), CR rates were 89% (8/9) at 200 mg and 100% (6/6) at 400 mg, with 100% CRc at both dose levels. Median (range) times to first CRc were 5.3 (4.6–14.0) and 4.9 (4.3–11.6) wks, respectively. Among evaluable CRc responders across both dose levels, 57% (8/14) achieved local NPM1 MRD negativity; of these, 7 were MRD negative by the end of 2 cycles of intensive therapy. Central NPM1/FLT3 MRD results will be presented. Among CRc responders, median times to neutrophil recovery ≥1×109/L were 44.0d (IQR 39–52) and 33.0d (IQR 29–42) for 200 mg and 400 mg, respectively; median times to platelet recovery ≥100×109/L were 36.5d (IQR 28–44) and 31.0d (IQR 28–37). At time of data cutoff, the 600 mg cohort was fully enrolled, and updated data will be presented across all doses (200, 400, and 600 mg).

Conclusions: In the ongoing KOMET-007 study, ziftomenib combined with 7+3 and quizartinib was well tolerated and demonstrated encouraging preliminary clinical activity in ND NPM1-m/FLT3-ITD+ AML. The combination resulted in low rates of ziftomenib-related cytopenias, no DLTs, no differentiation syndrome, and one investigator-assessed Gr≥3 QTc prolongation event that was unrelated to ziftomenib and successfully resolved. This regimen achieved 100% CRc after a median of ~5 wks, with 57% local CRc MRD negativity. Together, these data support further clinical development of ziftomenib and FLT3 inhibitor combinations in NPM1/FLT3-ITD+ AML.

Jesus D Gonzalez-Lugo, MD: Kura Oncology - Consultancy (Includes expert testimony)